Protagonist Therapeutics 股票：选择退出后成为生物技术版税复利公司 (NASDAQ:PTGX)
· seekingalpha.com
Protagonist Therapeutics 已演变为一家拥有两种FDA批准药物的版税驱动型公司。了解为何PTGX股票值得买入。
I last covered Protagonist Therapeutics ( PTGX ) about four months ago, in June, when rusfertide was still under priority review and the company held roughly $6...